Tanespimycin (17-AAG) Liposomes, Formulation XT28.1
995 EUR
In Stock
quantity
Produktdetaljer
Katalognummer: 1142 - DLL-0011-2ML
Produktkategori: Företag och industri > Vetenskap och laboratorium
Gentaur
Storlek: 2mL
Parameters
| Additional information | 300 mM sucrose |
|---|
DLL-0011-10ML
Tanespimycin (17-AAG) Liposomes, Formulation XT28.1
PEGylated liposomes containing Hsp90 inhibitor Tanespimycin (17-AAG). Tanespimycin exhibits 100-fold higher binding affinity to HSP90 derived from tumor cells vs normal cells, and induces apoptosis, necrosis, autophagy, and mitophagy. Tanespimycin is insoluble in aqueous media. This product is a pre-formulated liposomal version of Tanespimycin which is supplied ready to use in vitro or in vivo. The liposomes are PEGylated for optimal in vivo performance. For preclinical research use only.
2995 €
DLL-0011-2ML
Tanespimycin (17-AAG) Liposomes, Formulation XT28.1
PEGylated liposomes containing Hsp90 inhibitor Tanespimycin (17-AAG). Tanespimycin exhibits 100-fold higher binding affinity to HSP90 derived from tumor cells vs normal cells, and induces apoptosis, necrosis, autophagy, and mitophagy. Tanespimycin is insoluble in aqueous media. This product is a pre-formulated liposomal version of Tanespimycin which is supplied ready to use in vitro or in vivo. The liposomes are PEGylated for optimal in vivo performance. For preclinical research use only.
995 €
Håll dig uppdaterad! Visa tidigare publikationer
By: Author , 2 Comment
Pneumokocker – vad är det som angriper våra barn?
30 August 2025
By: Author , 2 Comment
Anaplasmos hos hundar och katter – allt du behöver veta
23 August 2025
By: Author , 2 Comment
Solbränna – hur leker man säkert i solen?
16 August 2025
By: Author , 2 Comment
Stroke – viktig information
8 August 2025